Kelley Coffman D'Annibale, MD
Gastrointestinal Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Cancers of the Gastrointestinal Tract
- Liver and Biliary Tract Cancers
- Colon & Rectal Cancers
About Me
- Assistant Attending Physician
I am a medical oncologist who specializes in diagnosing and treating cancers of the gastrointestinal tract (GI) including:
- Liver cancer
- Biliary tract cancers
- Small bowel and colorectal cancer
- Gastrointestinal neuroendocrine tumors
- Pancreatic cancer
- Esophageal cancer
- Stomach cancers
I see patients at Memorial Hospital in Manhattan and Memorial Sloan Kettering Monmouth in New Jersey.
Read more
After training in internal medicine during my residency, I specialized as an oncologic hospitalist in gastrointestinal cancers at Memorial Sloan Kettering Cancer Center (MSK) for several years. During this time, I gained insight into the intense physical and emotional toll of cancer and cancer treatments on a person. While helping patients through the medical complications of this disease, I became well-versed in a comprehensive approach to treatment which involves supporting a patient in every aspect from pain and symptom management to nutrition.
Inspired by my patients, I returned to specialize in medical oncology at the National Cancer Institute where my clinical research focused on early-phase clinical trials for liver cancer, biliary tract cancers, and tumors that have metastasized or spread to the liver. These clinical trials examined novel combinations of immunotherapies and adoptive cellular therapy—a personalized immunotherapy treatment that uses a person’s immune cells to help the body fight cancer.
I am committed to maintaining MSK’s history of excellence by ensuring access to the resources and expertise within the MSK network through multidisciplinary collaborations and innovative clinical trials. My goal is to ease the burden of receiving a cancer diagnosis and intensive therapies to prolong and improve quality of life.
Outside of medicine, I love watching Broadway shows and playing with my daughter and dog (an Australian Shepherd) in the park.
A gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
My Specialties
- Cancers of the Gastrointestinal Tract
- Liver and Biliary Tract Cancers
- Colon & Rectal Cancers
- Neuroendocrine Cancers
- Immunotherapy for Gastrointestinal Cancers
Education
- MD, Georgetown University School of Medicine
Residencies
- Internal Medicine, New York University School of Medicine
Fellowships
- Medical Oncology (Chief Fellow), National Cancer Institute/ National Institutes of Health
Board Certifications
- Medical Oncology, Internal Medicine
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. D'Annibale sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Coffman-D’Annibale K, Myojin Y, Monge C, Xie C, Hrones DM, Wood BJ, Levy EB, Kleiner DE, Figg WD, Steinberg SM, Redd B, Greten TF. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastatic cancer: a single center, single arm, phase II trial. J Immunother Cancer. 2024 Jan 6; 12(1): e008079. PMID: 38184304.
Coffman-D’Annibale K, Xie C, Hrones DM, Ghabra S, Greten TF, Monge C. The Current Landscape of Therapies for Hepatocellular Carcinoma. Carcinogenesis. 2023. Oct 20; 44(7): 537-548. PMID: 37428789.
Coffman-D’Annibale KL, Greten TF. Top advances of the year: hepatobiliary cancers. Cancer. 2023 Apr 15;129(8):1149-1155. PMID: 36692965.
Monge C*, Xie C*, Myojin Y*, Coffman K, Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, Hewitt SM, Kleiner DE, Steinberg SM, Figg WD, Redd B, Homan P, Cam M, Ruf B, Duffy AG, Greten TF. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. J Immunother Cancer. 2023 Feb; 11(2): e005640. PMID: 36754451.
Raj N, Coffman K, Le T, Do RKG, Rafailov J, Choi Y, Chou JF, Capanu M, Dunphy M, Fox JJ, Grewal RK, Reddy RP, Riedl C, Schoder H, Bodei L, Reidy-Lagunes D. Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE. Neuroendocrinology. 2022; 112(12): 1177-1186. PMID: 35609558.
Visit PubMed for a full listing of Dr. D'Annibale’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.